CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
bromfenac ophthalmic solution 0.06%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00758784
NCT00758784Phase 2Completed
CompareCT.gov

Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease

Bausch & Lomb Incorporated·interventional·Posted Sep 25, 2008·Updated Sep 14, 2020

In Brief

A Phase 2 clinical trial evaluating bromfenac ophthalmic solution 0.06% for Dry Eye Disease. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the safety and efficacy of an ophthalmic solution in dry eye disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 25, 2008
Enrollment StartAug 13, 2008
Primary CompletionJan 14, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.8 years ago

Interventions

bromfenac ophthalmic solution 0.06%drug

bromfenac ophthalmic solution 0.06% bilaterally twice a day